The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kewalramani Reshma since 2018.
This trader's CIK number is 1735944.
At the time of last reporting, Kewalramani Reshma was the CEO & President of Vertex Pharmaceuticals Inc / Ma. (stock ticker symbol VRTX).
Also see all insider trading activities at Vertex Pharmaceuticals Inc / Ma.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | VRTX | 10,000 | $3,895,150 | 0 | $0 | 0 | $0 |
| 2024 | VRTX | 0 | $0 | 45,602 | $22,177,658 | 0 | $0 |
| 2023 | VRTX | 0 | $0 | 48,475 | $17,974,772 | 17,135 | $2,939,509 |
| 2022 | VRTX | 0 | $0 | 23,378 | $6,970,851 | 0 | $0 |
| 2021 | VRTX | 10,000 | $1,957,400 | 0 | $0 | 0 | $0 |
| 2020 | VRTX | 0 | $0 | 11,137 | $2,795,942 | 6,221 | $1,067,211 |
| 2019 | VRTX | 0 | $0 | 10,686 | $2,190,929 | 8,258 | $1,434,652 |
| 2018 | VRTX | 0 | $0 | 2,305 | $430,919 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | DNA | 0 | $0 | 0 | $0 | 9,818 | $0 |
1. Vertex Pharmaceuticals Inc / Ma (VRTX)
2. Ginkgo Bioworks Holdings, Inc. (DNA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-06 | VRTX | Buy | 10,000 | 389.51 | 3,895,150 |
| 2024-11-08 | VRTX | Sale | 15,198 | 515.00 | 7,826,970 |
| 2024-07-22 | VRTX | Sale | 15,202 | 497.00 | 7,555,394 |
| 2024-05-20 | VRTX | Sale | 15,202 | 447.00 | 6,795,294 |
| 2023-12-15 | VRTX | Sale | 17,135 | 407.00 | 6,973,945 |
| 2023-12-15 | VRTX | Option Ex | 17,135 | 171.55 | 2,939,509 |
| 2023-12-13 | VRTX | Sale | 5,098 | 397.00 | 2,023,906 |
| 2023-11-13 | VRTX | Sale | 5,097 | 377.00 | 1,921,569 |
| 2023-07-17 | VRTX | Sale | 7,828 | 355.00 | 2,778,940 |
| 2023-04-27 | VRTX | Sale | 3,317 | 339.44 | 1,125,912 |
| 2023-01-25 | VRTX | Sale | 10,000 | 315.05 | 3,150,500 |
| 2022-08-15 | VRTX | Sale | 11,689 | 305.06 | 3,565,846 |
| 2022-06-24 | VRTX | Sale | 11,689 | 291.30 | 3,405,005 |
| 2021-08-19 | VRTX | Buy | 10,000 | 195.74 | 1,957,400 |
| 2020-08-06 | VRTX | Option Ex | 2,073 | 171.55 | 355,623 |
| 2020-08-06 | VRTX | Sale | 2,073 | 271.38 | 562,579 |
| 2020-05-15 | VRTX | Sale | 99 | 282.12 | 27,930 |
| 2020-05-06 | VRTX | Option Ex | 2,074 | 171.55 | 355,794 |
| 2020-05-06 | VRTX | Sale | 2,074 | 272.85 | 565,890 |
| 2020-02-25 | VRTX | Sale | 3,634 | 234.60 | 852,554 |
| 2020-02-18 | VRTX | Sale | 1,183 | 243.76 | 288,363 |
| 2020-02-06 | VRTX | Option Ex | 2,074 | 171.55 | 355,794 |
| 2020-02-06 | VRTX | Sale | 2,074 | 240.42 | 498,626 |
| 2019-11-25 | VRTX | Sale | 4,692 | 219.37 | 1,029,284 |
| 2019-11-25 | VRTX | Option Ex | 4,692 | 187.53 | 879,890 |
| 2019-11-15 | VRTX | Sale | 61 | 205.95 | 12,562 |
| 2019-11-08 | VRTX | Option Ex | 509 | 155.57 | 79,185 |
| 2019-11-08 | VRTX | Sale | 509 | 199.00 | 101,291 |
| 2019-10-30 | VRTX | Sale | 3,057 | 199.00 | 608,343 |
| 2019-10-30 | VRTX | Option Ex | 3,057 | 155.57 | 475,577 |
| 2019-10-22 | VRTX | Sale | 638 | 189.00 | 120,582 |
| 2019-05-15 | VRTX | Sale | 241 | 165.41 | 39,863 |
| 2019-02-19 | VRTX | Sale | 1,488 | 187.50 | 279,004 |
| 2018-10-08 | VRTX | Sale | 2,305 | 186.95 | 430,919 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-09-30 | DNA | Option Ex | 9,818 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kewalramani Reshma (CEO & President of Vertex Pharmaceuticals Inc / Ma at the time of this reporting) see the Securities and Exchange Commission (SEC) website.